Lanham O'Dell & Company, Inc. Ocugen, Inc. Transaction History
Lanham O'Dell & Company, Inc.
- $276 Million
- Q4 2025
A detailed history of Lanham O'Dell & Company, Inc. transactions in Ocugen, Inc. stock. As of the latest transaction made, Lanham O'Dell & Company, Inc. holds 100,000 shares of OCGN stock, worth $119,000. This represents 0.04% of its overall portfolio holdings.
Number of Shares
100,000
Previous 140,000
28.57%
Holding current value
$119,000
Previous $228,000
47.81%
% of portfolio
0.04%
Previous 0.09%
Shares
7 transactions
Others Institutions Holding OCGN
# of Institutions
105Shares Held
61.4MCall Options Held
531KPut Options Held
433K-
Black Rock Inc. New York, NY17.9MShares$21.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.2MShares$18.1 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.16MShares$4.95 Million0.0% of portfolio
-
Gmt Capital Corp Atlanta, GA4.15MShares$4.94 Million0.31% of portfolio
-
Geode Capital Management, LLC Boston, MA3.68MShares$4.38 Million0.0% of portfolio
About Ocugen, Inc.
- Ticker OCGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 216,566,000
- Market Cap $258M
- Description
- Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...